Customize
Quick Links

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by and educational grant from AstraZeneca.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

AACR: Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care

AACR: Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care


Monday, April 1, 2019
6:30 PM – 7:00 PM Registration & Dinner
7:00 PM - 9:00 PM Program

Atlanta Hyatt Regency
International North and South
265 Peachtree St NE
Atlanta, GA 30303

Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers Overview:

Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care is a live symposium to be held adjunct to the AACR annual meeting in Atlanta. Diagnosis, molecular testing, treatment decision-making, and sequencing in the management of patients with advanced, epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer (NSCLC) continues to change as new evidence emerges. The development of next-generation agents and new molecular testing modalities make it imperative that all members of the multidisciplinary care team understand both the new data and best practices to practically apply EGFR inhibitors to patient care, including methods that proactively plan to manage and mitigate treatment-related toxicities.

To meet these educational needs, this cutting-edge symposium will explore considerations in first-line therapy, including scenarios with de novo resistance mutations; approaches to managing resistance to therapy, including the role of molecular testing; and managing central nervous system (CNS) metastases. This activity will provide you with the opportunity to learn from a panel of world-class experts in lung cancer who will review recent practice-changing data and state-of-the-art approaches for patients with EGFR mutation–positive NSCLC, with an emphasis on examining the evidence and trial data, and how to interpret and apply those data in your practice. Be sure to join us in Atlanta for expert advice on optimal treatment paradigms for patients with NSCLC and EGFR mutations. This is a symposium that you won’t want to miss!

Benefits of attending Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care:

  • Gain insights into the use of liquid-based and tissue-based testing methods to choose the best therapy for patients with EGFR mutation–positive NSCLC
  • Learn about the latest clinical data on first-line treatment of patients with NSCLC and EGFR mutations
  • Expand knowledge of approaches to manage patients whose disease progresses on EGFR inhibitor therapy
  • Develop strategies to manage treatment-related toxicities in patients with EGFR mutation–positive NSCLC

Acknowledgment of Commercial Support

This activity is supported by and educational grant from AstraZeneca.

Learning Objectives

Upon successful completion of this activity, oncologists who attend should be better prepared to:

  • Evaluate liquid biopsies and other molecular testing approaches to optimize selection in the first-line setting and subsequent lines of therapy for patients with advanced NSCLC
  • Describe key clinical data informing initial treatment of patients with EGFR mutation–positive NSCLC
  • Assess clinical data regarding the management of acquired resistance and disease progression in patients with EGFR mutation–positive NSCLC
  • Discuss interventions for patients with EGFR mutation–positive NSCLC and CNS metastases and/or treatment-related adverse events

Program Chair for Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
2425262728
Filter By